- Home
- GENK vs APM Comparison
GENK vs APM Comparison
Compare GENK & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | APM |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United Kingdom |
| Employees | 2700 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 7.5M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GENK | APM |
|---|---|---|
| Price | $1.54 | $0.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | 47.0K | ★ 66.1K |
| Earning Date | 05-12-2026 | 03-31-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $15.02 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.43 | $0.65 |
| 52 Week High | $4.98 | $4.47 |
Technical Indicators
Market Signals| Indicator | GENK | APM |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 50.42 |
| Support Level | $1.46 | $0.77 |
| Resistance Level | $2.55 | $1.11 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 28.95 | 55.23 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.